rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E mutation is a distinctive genomic alteration of pediatric low-grade gliomas with prognostic and therapeutic implications.
|
31667545 |
2020 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E mutation is a distinctive genomic alteration of pediatric low-grade gliomas with prognostic and therapeutic implications.
|
31667545 |
2020 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Whereas both H3F3A K27M and BRAF V600E have been reported as poor prognostic markers in pediatric glioma, our case, along with several other reported cases, suggests that the coexistence of these two mutations might not indicate poor prognosis.
|
31254135 |
2019 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Whereas both H3F3A K27M and BRAF V600E have been reported as poor prognostic markers in pediatric glioma, our case, along with several other reported cases, suggests that the coexistence of these two mutations might not indicate poor prognosis.
|
31254135 |
2019 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF-V600E mutations are most commonly found in pleomorphic xanthoastrocytoma, ganglioglioma, epithelioid glioblastoma, and gliomas diagnosed at a younger age; BRAF-KIAA1549 fusion is the most common BRAF alteration in pilocytic astrocytoma.
|
30265855 |
2018 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Taken together with the facts that only one PXA preceded E-GBM among these lower-grade lesions, and that co-occurrence of BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions have been reported to be rare in conventional lower-grade diffuse gliomas, the diffuse glioma-like components may be distinct infiltrative components of E-GBM, reflecting intratumoral heterogeneity.
|
29105198 |
2018 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Additionally, BRAF V600E was only associated with a favorable prognosis in lower grade glioma.
|
28534272 |
2018 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF-V600E mutations are most commonly found in pleomorphic xanthoastrocytoma, ganglioglioma, epithelioid glioblastoma, and gliomas diagnosed at a younger age; BRAF-KIAA1549 fusion is the most common BRAF alteration in pilocytic astrocytoma.
|
30265855 |
2018 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Taken together with the facts that only one PXA preceded E-GBM among these lower-grade lesions, and that co-occurrence of BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions have been reported to be rare in conventional lower-grade diffuse gliomas, the diffuse glioma-like components may be distinct infiltrative components of E-GBM, reflecting intratumoral heterogeneity.
|
29105198 |
2018 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Additionally, BRAF V600E was only associated with a favorable prognosis in lower grade glioma.
|
28534272 |
2018 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A phase I/II clinical trial suggests that dabrafenib shrinks or stabilizes low-grade gliomas in children with the BRAF V600E mutation.
|
28062673 |
2017 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas.
|
28727518 |
2017 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas.
|
28727518 |
2017 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We were unable to find other examples of glial tumors in public databases with this rare BRAF V600D mutation.
|
27860162 |
2017 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A phase I/II clinical trial suggests that dabrafenib shrinks or stabilizes low-grade gliomas in children with the BRAF V600E mutation.
|
28062673 |
2017 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma.
|
26384810 |
2016 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These findings are consistent with clonal expansion of a morphologically distinct focus, harboring a private BRAF V600E mutation within an IDH1-mutant glioma.
|
26414224 |
2016 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
For colorectal carcinoma, thyroid cancer, malignant melanoma and gliomas BRAF V600E immunostaining is sufficient for screening purposes.
|
27350555 |
2016 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We discuss differential diagnosis of the tumor, and review previously described diffuse gliomas with the BRAF V600E mutation.
|
26445861 |
2016 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These findings are consistent with clonal expansion of a morphologically distinct focus, harboring a private BRAF V600E mutation within an IDH1-mutant glioma.
|
26414224 |
2016 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma.
|
26384810 |
2016 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We discuss differential diagnosis of the tumor, and review previously described diffuse gliomas with the BRAF V600E mutation.
|
26445861 |
2016 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
For colorectal carcinoma, thyroid cancer, malignant melanoma and gliomas BRAF V600E immunostaining is sufficient for screening purposes.
|
27350555 |
2016 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We demonstrated that overexpression of PTPN9 reduces EGFR phosphorylation and cooperates with BRAF(V</span>600E</span>) in</span>hibitor PLX4720 to reduce MAPK and Akt signaling, resulting in decreased glioma cell viability.
|
26023796 |
2015 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our data indicate that BRAF(V600E) is a common genetic alteration in low-grade glial tumors with neuronal component or differentiation.
|
25346165 |
2015 |